<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149641">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856088</url>
  </required_header>
  <id_info>
    <org_study_id>Scitech 004</org_study_id>
    <nct_id>NCT01856088</nct_id>
  </id_info>
  <brief_title>DESTINY TRIAL (Inspiron x Biomatrix)</brief_title>
  <official_title>Stents Coated With the Biodegradable Polymer on Their Faces and Elution of Sirolimus Abluminais Versus Elution Biolimus for the Treatment of Coronary Lesions Again - Randomized Destiny</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the effectiveness of stent Inspiron ™
      sirolimus-eluting and coating the abluminal biodegradable stent Biomatrix Flex ™ lesions in
      native coronary arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study of non-inferiority, multicentre, prospective, randomized into two treatment
      arms: I) Inspiron ™ stent eluting sirolimus or II) ™ Biomatrix stent eluting biolimus. Are a
      total of 165 randomized patients.

      Patients will be followed for 60 months after the procedure. All new patients will be
      undergoing angiography for evaluation at 9 months. A subgroup of 60 patients will be
      evaluated with volumetric intravascular ultrasound at 9 months. Also, a subgroup of 21
      patients will be evaluated with optical coherence tomography at the end of the index
      procedure and 9 months. It is anticipated that the total study duration is 72 months: 12
      months to complete the admission of patients and 60 months of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lumen Loss</measure>
    <time_frame>9 months after the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>For an accurate assessment of the stent conditions 9 months after implantation, a follow-up catheterization will be performed at the 9 months visit in order to measure the diameter of the artery at the stented site.
A subgroup of 60 patients will be evaluated with volumetric intravascular ultrasound at 9 months. Also, a subgroup of 21 patients will be evaluated with optical coherence tomography at the end of the index procedure and 9 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Cardiac Events</measure>
    <time_frame>30 days, 4, 9, 12 months and 2, 3, 4, 5 years after the procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The clinical follow-up should be performed during the index procedure at 30 days, 4, 9, 12 months and 2, 3, 4, 5 years after the procedure, and should consist of an assessment of the angina status (according to the Canadian Cardiovascular Society Classification and the Braunwald for unstable angina) and major adverse cardiac avents and any interventional treatment (e.g: repeated targetlesion revascularization or recurrent ischemia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stent Inspiron with Sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stent Biomatrix Flex with biolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inspiron ™ stent eluting sirolimus or   Biomatrix™  stent eluting biolimus</intervention_name>
    <description>Site preparation acces should be performed as per standard hospital procedures It is recommended to cross the target lesion with 0,014 inch exchange-lenght guide wire. If necessary the involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care. A stent consists of an endovascular prosthesis with a metalic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.</description>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <other_name>Drug eluting stent</other_name>
    <other_name>Angiography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years;

          2. Symptomatic ischemic heart disease and / or objective evidence of myocardial ischemia
             with one or two target lesions located in different epicardial vessels;

          3. A(s) lesion(s) to target(m) must be:

               1. Again (not restenotic);

               2. Located in a native coronary artery diameter from 2.5 to 3.5 mm (visual);

               3. Can be treated with a single stent up to 29 mm in length;

               4. Obstruction with stenosis &gt; 50% diameter (visual);

          4. Acceptable candidate for CABG;

          5. The patient will be informed of the nature of the study, agree with their rules and
             provide a written informed consent approved by the local Ethics Committee.

        Exclusion Criteria:

          1. Women of childbearing age with no history of surgical sterilization;

          2. Myocardial infarction with Q wave occurred in the last 48 hours before the index
             procedure;

          3. Myocardial infarction with or without Q wave with cardiac markers even at high
             levels;

          4. Ejection fraction &lt; 30%;

          5. Impaired renal function (creatinine&gt; 2.0 mg / dl) or calculated creatinine clearance
             &lt; 60 ml / min;

          6. Platelet count &lt;100,000 cells/mm3 or &gt; 700,000 cells/mm3;

          7. Total leukocyte count &lt;3000 cells/mm3;

          8. Documented or suspected liver disease (including laboratory evidence of hepatitis);

          9. Heart transplant recipient;

         10. Known allergies to aspirin, clopidogrel, ticlopidine, paclitaxel, sirolimus, heparin
             or stainless steel;

         11. Patient with a life expectancy less than 12 months;

         12. Any significant medical condition which in the opinion of the investigator would
             interfere with the ideal of patient participation in this study;

         13. Participation in other research in the last 12 months, unless there is direct benefit
             to the research subject;

         14. Coronary angioplasty (with or without stenting) for less than 6 months anywhere in
             the target vessel;

         15. Coronary angioplasty (with or without stenting) prior to any time in that segment
             Diste less than 5 mm (proximal or distal) of the lesion;

         16. Coronary angioplasty (with or without stenting) scheduled in the first 12 months
             after the index procedure in any segment of the target vessel.

        EXCLUSION CRITERIA angiographic

          1. Restenotic target lesion;

          2. Need for treatment for more than one lesion in the same vessel;

          3. Need for treatment with three or more lesions in the same procedure;

          4. Target vessel diameter &lt;2.5 mm or&gt; 3.5 mm (visual);

          5. Target lesion long not susceptible to treatment with a single stent to 29mm in
             length, according to the judgment of the operator;

          6. Lesion of the coronary artery unprotected ( &gt; 50% stenosis);

          7. Angiographic thrombus;

          8. Target lesion in surgical graft;

          9. Total occlusion (TIMI anterograde flow 0 or 1);

         10. Ostial lesion;

         11. The target lesion bifurcation with side branch that may require intervention during
             the procedure, with or without stenting;

         12. Injuries that are impossible to anticipate predilatation successfully or that is
             necessary to use rotablator;

         13. The target vessel with excessive tortuosity.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Lemos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Coração - Incor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adriana Gouveia, nursing</last_name>
    <phone>55 11 98920-2999</phone>
    <email>adriana.gouveia@cmsmedical.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Pereira, Medicine</last_name>
    <phone>55 11 2661 5368</phone>
    <email>patricia.pereira@incor.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Santa Izabel</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline de Souza Bernardes Reis</last_name>
      <phone>55 71 2203-8476</phone>
      <email>npcardio@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adriano Dourado, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intercath Meridional</name>
      <address>
        <city>Cariacica</city>
        <state>ES</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Paula Oliveira</last_name>
      <phone>55 27 3346-2121</phone>
      <email>anapaula@intercath.com.br</email>
    </contact>
    <investigator>
      <last_name>Bruno Moulin Machado, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Encore - Cardiologia e Radiologia Intervencionista</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara Rubia Rocha</last_name>
      <phone>55 62 3230-1825</phone>
      <email>pesquisaclinica@encore.med.br</email>
    </contact>
    <investigator>
      <last_name>Mauricio Prudete, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Cardiologico Costantini</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danilo , Nursing</last_name>
      <phone>55 41 3013-9266</phone>
      <email>pesquisa@hospitalcostantini.com.br</email>
    </contact>
    <investigator>
      <last_name>Costantino Costantino, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonieta Moraes, Nursing</last_name>
      <phone>55 51 3230-3678</phone>
      <email>pesquisaclinica@cardiologia.org.br</email>
    </contact>
    <contact_backup>
      <last_name>Silvia , Nursing</last_name>
      <phone>55 51 3230-3678</phone>
      <email>pesquisaclinica@cardiologia.org.br</email>
    </contact_backup>
    <investigator>
      <last_name>Rogério E. Gomes Sarmento Leite, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Assistência Médica ao Servidor Publico Estadual</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Mizuno, Nursing</last_name>
      <phone>55 11 50837001</phone>
      <email>emiliamizuno@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>George Ximenes Meireles, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Viana, Medicine</last_name>
      <phone>55 11 5085-6325</phone>
      <email>rviana@dantepazzanese.org.br</email>
    </contact>
    <investigator>
      <last_name>Alexandre Abizaid, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pereira, Biomedicine</last_name>
      <phone>55 11 2661-5377</phone>
      <email>patricia.pereira@incor.usp.br</email>
    </contact>
    <investigator>
      <last_name>Expedito E. Ribeiro da Silva, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Mariani Júnior, Medicine</last_name>
      <phone>55 11 2176-7000</phone>
      <email>marianijr@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>José Mariani Júnior, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Bandeirantes de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Regina Bardel, nursing</last_name>
      <phone>55 11 3345-2476</phone>
      <email>s.baradel@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Stefania Rodrigues Pereira, Nursing</last_name>
      <phone>55 11 3345-2476</phone>
      <email>stefaniaenfermagem@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Cantarelli, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helio Castello, Medicine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Kitze</last_name>
    </contact>
    <investigator>
      <last_name>Marco Antonio Perin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.scitechmed.com</url>
    <description>Sponsor site</description>
  </link>
  <link>
    <url>http://portal2.saude.gov.br/sisnep</url>
    <description>National Information System on Ethics in Research Involving Human</description>
  </link>
  <link>
    <url>http://www.dantepazzanese.org.br</url>
    <description>Site about the location thet wiil be done the study. Location where the principal investigator works.</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>December 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery</keyword>
  <keyword>Drug eluting stent</keyword>
  <keyword>thrombosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
